2 results
Approved WMOPending
The primary objective of the clinical performance study is to demonstrate the clinical performance of VENTANA PD-L1 (SP263) CDx Assay in terms of its ability to identify NSCLC patients who may benefit from treatment with volrustomig plus…
Approved WMOPending
Our primary objective is to investigate the change in dyspnea severity after 4 weeks of the use of the PEP-buddy. Secondary objectives are to investigate the patient satisfaction level and use of the device, the effect on quality of life and COPD…